CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CARsgen Therapeutics Holdings Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CARsgen Therapeutics Holdings Ltd
Building 12
No.388 Yindu Road, Xuhui District
SHANGHAI, SHA  KY1-1205  China Ticker: 21712171
Business Summary
CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer, Chief Scientific Officer ZonghaiLi 48 2/1/2021 10/1/2014
President of CARsgen Therapeutics Corporation Richard J.Daly 71 1/1/2022 1/1/2022
Chief Operating Officer, Executive Director HuamaoWang 45 2/1/2021 9/13/2018
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
CAFA THERAPEUTICS LIMITED 2/3 Exchange Place IFSC Ireland
CARsgen Pharmaceuticals Co., Ltd 12F, 14F, No.506, Shangcheng Rd Shanghai China
CARsgen Therapeutics Corporation 4022 Stirrup Creek Drive Durham NC United States
CARsgen Therapeutics Co Ltd Building 12 SHANGHAI SHA China

Business Names
Business Name
2171
CAFA Therapeutics Limned
CARsgen Diagnostics Co., Ltd
8 additional Business Names available in full report.

General Information
Number of Employees: 477 (As of 6/30/2024)
Outstanding Shares: 571,539,915 (As of 7/31/2024)
Stock Exchange: HKG


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024